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 ABSTRACT 
 
OBJECTIVE: The objective of this systematic review is to determine whether or not “Are 
inverse agonists of the Histamine H3 receptor effective in reducing excessive daytime sleepiness 
(EDS) in individuals with sleep disorders?”  
 
DESIGN: Review of two randomized controlled trials and one cross-sequential pilot study. All 
studies were primary sources, published in the English language and from 2008-2017. 
 
DATA SOURCES: A single-blind, placebo controlled, cross-sequential study comparing an H3 
inverse agonist to placebo in narcoleptics. Two randomized, double-blind, placebo controlled 
studies; one in narcoleptic patients and one in obstructive sleep apnea (OSA) patients. All studies 
found using PubMed and Cochrane databases.     
 
OUTCOMES MEASURED: All three trials assessed the efficacy of using an H3 inverse agonist 
to reduce EDS symptoms in patients with either narcolepsy or obstructive sleep apnea. EDS 
severity was assessed using the Epworth Sleepiness Scale (ESS), an eight question self-
administered questionnaire that assess an individual’s likelihood of falling asleep in normal 
everyday settings. Scores range 0-24, with a higher score correlating with more severe EDS.  
 
RESULTS: The pilot study done by Lin J-S et al. showed a significant reduction in ESS score of 
4.86 (p =0.0006). The RCT done by Dauvilliers (2013) concluded with a significant ESS score 
reduction of -3.0 (p= 0.024) when compared to placebo. The final study involving OSA patients 
done by Herring et al. showed a larger reduction in ESS scores when treated with an H3 inverse 
agonist compared to treatment with a placebo. These results were not proven to be statistically 
significant.  
 
CONCLUSIONS: These results suggest that H3 inverse agonists are effective at reducing EDS 
symptoms in patients with sleep disorders. All three studies provided evidence of reduced ESS 
scores, indicating a perceived improvement in EDS symptoms with the use of an H3 inverse 
agonist. Two of the three studies provided statistically significant reductions ESS scores when 
compared to placebo.  
 
KEY WORDS: Narcolepsy, Sleep Apnea, Excessive Daytime Sleepiness (EDS)  
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Introduction 
“I’m always tired” is one of the few complaints physicians and physician assistants dread 
to hear. Fatigue and excessive tiredness is a sensitive but also nonspecific indicator for many 
underlying conditions in a variety of medical settings. Determining the cause of a patient’s 
fatigue can be a long and frustrating process for both the doctor and the patient. However, what 
is even more frustrating is knowing the source of the fatigue but not being able to adequately 
treat the patient. Unfortunately, this is the discouraging truth for many patients with sleep 
disorders who suffer from excessive daytime sleepiness (EDS).  
EDS is a universal symptom of almost all sleep disorders. It is defined as the inability to 
maintain wakefulness and alertness during the major waking episodes of the day, with sleep 
occurring unintentionally or at inappropriate times almost daily for at least three months. 1 EDS 
affects nearly 20% of the US population,2 however it’s true prevalence is difficult to estimate due 
to the subjective nature of the symptoms and inconsistencies in terminology (ie – fatigue, 
drowsiness, sluggishness). EDS can lead to cognitive impairment, immune suppression, and 
decreased quality of life. If not properly managed, EDS can lead to unnecessary health care costs 
and motor vehicle accidents.  Narcolepsy and Obstructive Sleep Apnea (OSA) are two sleep 
disorders commonly recognized for severe EDS. 
 Narcolepsy is a sleep disorder that effects 1 out of every 2,000 Americans.3 It is well 
known for its unique “sleep attacks” in which individuals suddenly fall into a deep sleep at a 
moment’s notice. The etiology of narcolepsy is still not fully understood, but it is thought to be 
caused by a deficiency in hypocretin, a brain chemical that regulates sleep. It’s most debilitating 
symptom is EDS, which occurs in 100% of individuals with the disorder.4 Treatment involves 
the use of drugs to try to regulate the sleep-wake cycle. Modafinil is the current gold standard in 
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treating the symptoms of EDS in narcoleptic patients.4 Additional CNS stimulants, such as 
methylphenidate and amphetamines, may also be used when modafinil is insufficient. Prior to 
modafinil, sodium oxybate was considered the first line treatment, and is still frequently used 
today.  
It is estimated that 22 million Americans suffer from obstructive sleep apnea.3 EDS is 
present in 70% of patients with OSA and is the most common daytime symptom.5 The defining 
pathological event of OSA is the closure of the upper airway during sleep, resulting in apneic 
events, or pauses in breathing.6 The closure of the airway is thought to occur due to the failure of 
the genioglossus and other upper airway dilator muscles. Failure of these muscles can be a result 
of several factors including obesity, neck circumference >17 inches, and tonsillar hypertrophy. 6 
Apneic events are relieved by sudden brain activation and arousal. The cyclic nature of these 
apneic events and brain activation leads to fragmented sleep and poor sleep quality. Continuous 
positive airway pressure (CPAP) is considered the gold standard of treatment for OSA. With 
optimal adherence, CPAP improves sleep quality. However, one study showed that even with 
optimal adherence, 22% of patients reported residual symptoms of EDS.7 This, in combination 
with already low adherence rates, EDS continues to be a major problem in this population.  
The prevalence of sleep disorders comes with a high cost. In the US, it is estimated to be 
between $50 and $100 billion dollars. Patients with narcolepsy are often on full disability and 
annual medical costs are often twice as much as matched controls.8 In the workplace, sleepiness 
results in the loss of $54 million/year due to reduced productivity9 and individuals with EDS are 
three times more likely to be involved in a workplace accident.10 Another study estimated that 
810,000 automobile accidents resulting in 1400 fatalities are attributable to OSA in a single 
year.11 By treating the same OSA patients with CPAP at 70% adherence, it was estimated that it 
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would prevent 500,000 collisions.11 However, this means that even with treatment with the 
current gold standard, there would still be 310,000 collisions with 400 fatalities at the cost of 
$4.8 billion. It is clear that an adjunctive treatment to EDS is needed.  
It has been well speculated that histamine plays a role in sleep and arousal ever since the 
sedating properties of antihistamines were first observed in the 1940’s.12 However, it hasn’t been 
until recently that we have begun to fully understand the complexity of the histaminergic system. 
In 1983, histamine H3 receptors were discovered to provide negative feedback on the synthesis 
of histamine. While activation of H1 and H2 receptors via histamine excite and arouse various 
neurons, H3 receptor activation actually has the opposite effect. When histamine binds to an H3 
receptor it triggers a negative feedback to restrict further histamine synthesis and release. An 
inverse agonist of this receptor would block the effects of the H3 receptor and exert the opposite 
effect by suppressing spontaneous receptor signaling.13 In other words, it would promote the 
release of more histamine and arousal. The discovery if this new H3 receptor has become a 
potential target for the pharmaceutical treatment of EDS. 
Objective:  
The objective of this systematic review is to determine whether or not inverse agonists of 
the Histamine H3 receptor are effective in reducing excessive daytime sleepiness (EDS) in 
individuals with sleep disorders.  
Methods:  
A detailed search of the PubMed database was completed between November 2016 and 
January 2017 using the keywords “narcolepsy”, “EDS”, and “sleep apnea”. Cochrane Systematic 
Reviews was also searched to rule out any previous systematic reviews or meta-analysis on the 
topic.  Articles were selected based on publication date, relevance to practice and importance to 
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patient-oriented outcomes (POEMs). Inclusion criteria included placebo-controlled trials 
comparing the efficacy of a H3 inverse agonist to that of a placebo. Two studies also compared 
the efficacy of modafinil compared to H3 inverse agonists and placebo. All studies included 
participants over the age of 18 with a clinically diagnosed sleep disorder published in an English 
peer reviewed journal after 2006. All participants reported having an ESS score of at least 10 or 
above prior to the start of the respected studies. Two double-blinded RCT’s comparing the 
pharmacological effects of a H3 inverse agonist were included in this review; one was a 
crossover design and the other was a parallel design. Due to the sparsity of published 
interventions involving H3 inverse agonists, a single-blind pilot study was also included in this 
review.  
Table 1: Demographics & Characteristics of included studies  
Study Type # Pts  Age 
(yrs) 
Inclusion Criteria: Exclusion Criteria:  W/
D 
Interventions:  
Lin J-S 
(2008) 
 
Cross 
Sequenti
al  
Study 
 
Single 
blind  
22 
 
 
 
14 ♂ 
8 ♀  
 
28-54 Diagnosis of narcolepsy 
via the International 
Classifications of Sleep 
Disorders 
 
Presence of severe  EDS 
for 3 months or greater  
ESS Score < 10  1 1 week of daily:  
 
40 mg capsule of tiprolisant 
(a histamine H3 inverse 
agonist)  
vs. 
 Visually matched placebo 
Dauvill
iers 
(2013) 
 
RCT  
 
 
Double 
blind/ 
parallel 
group 
design 
95 
 
 
51 ♂ 
44 
♀  
 
 
21-52  Age > 18 yo  
 
Must be diagnosed with 
narcolepsy and 
confirmed via 
polysomnogram. 
 
Self – reported EDS for 
more than 3 months.  
 
A ESS Score > 14 
 Women of child bearing 
age not on a birth 
control method 
 
Use of any 
investigational drug 
within 30 days of 
screening 
 
Any disorder that could 
be the main cause of 
EDS. 
 
Hx of substance abuse 
Cardiovascular, renal, 
hepatic disorders, or 
psychiatric disorder. 
16 8 weeks of treatment. 
 
Pitolisant (Histamine H3 
inverse agonist) 
vs. 
Visually matched placebo 
vs. 
Modafinil 
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Herring 
(2013) 
RCT 
 
 
 
Double 
blind/  
crossove
r design 
125  
 
 
 
100 
♂  
 
25 
♀  
 
18-64 >18 yo 
 
Diagnosed OSA and 
managed with cont. 
positive airway pressure 
therapy 
 
Use of compliant CPAP 
treatment for > 2months  
ESS >10  
 
Clinical global 
impressions-severity 
scale rating >4 
History of sleep 
disorders other than 
OSA.  
 
Medical conditions other 
than OSA that would 
explain EDS.  
 
6 MWT sessions 
performed at the end of 
placebo screening; pt’s 
excluded if they stayed 
awake throughout the 
30-min test for more 
than 2 of the 6 sessions. 
22 2 weeks each of daily: 
 
Modafinil (200mg), 
Visually matched placebo,  
and  
MK-0249 (5, 8, 10, or 
12mg) 
 
One week washout between 
intervention periods. 
 
 
Outcomes Measured:  
Reduction in EDS was measured in all three studies by using the Epworth Sleepiness 
Scale (ESS). The ESS is a self-administered questionnaire that assesses the likelihood of falling 
asleep in a variety of everyday situations. Respondents rate, on a 4-point scale (0-3), their 
probability of dozing off while engaged in eight different activities. The total ESS score is the 
sum of all 8 items, and can range from 0-24. The higher the score, the higher the person’s sleep 
propensity in daily settings, or their ‘daytime sleepiness’. The ESS questionnaire only takes 2-3 
minutes to complete, and is the most widely used clinical instrument for evaluating sleepiness.14  
Results:  
The two RCTs, and one pilot study included in this review compared the efficacy of H3 
receptor inverse agonists in reducing excessive daytime sleepiness when compared to placebo in 
individuals diagnosed with narcolepsy or obstructive sleep apnea.  
The single-blind pilot trial by Lin J-S et al.15 was one of the first studies that looked at the 
effects of a H3 inverse agonist in humans. The study consisted of 22 patients with diagnosed 
narcolepsy. All participants were recruited from the sleep medicine practices of 4 participating 
centers. All stimulant medications were stopped 3 days before the study. Participants consumed a 
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capsule daily containing a placebo for 1 week, followed by 1 week of daily consumption of 40 
mg of tiprolisant, an H3 inverse agonist. The study concluded with 21 participants. One 
participant failed to complete the study after experiencing adverse effects from the 
discontinuation of her previous medications prior to the study. The principal end-point of the 
study was changes in ESS scores at the end of each week. Each patient acted as his/her control. 
All analyses were performed on the intention-to-treat population (n=22).  The mean ESS score 
after 1 week of placebo and 1 week of tiprolisant were 16.66 (± 4.86) and 11.81 (± 6.11) 
respectively (Table 2).  
The t-tests, which compared the variables measured during the tiprolisant period versus 
placebo period, were performed only when both values were available (n=21). Significant 
differences in ESS were seen with Tiprolisant when compared to baseline and placebo. 
Specifically, the ESS score under tiprolisant treatment showed a 4.86 ± 5.12 point reduction 
when compared to placebo, and a 5.86 ± 5.51 reduction when compared to baseline (Table 3).  
Table 2: Mean ESS Score (±  SD) 
 Mean ESS Score (±  SD)  
Baseline   17.55 (± 3.89) 
After Placebo period  16.66 (± 4.86)  
After Tiprolisant period 11.81 (± 6.11)  
 
 
Table 3: Treatment Effect (Point Reduction [95% CI]; p-value) 
Tiprolisant vs placebo  Tiprolisant vs Baseline  
4.86 (2.22 to 7.56)  
p= 0.0006 
5.86  (3.42 to 8.34)  
p < 0.0001  
 
11 patients experienced 23 adverse events during tiprolisant treatment as compared to 7 
patients experiencing 13 adverse events during placebo treatment. Among the 22 patients the 
most significant adverse events during the tiprolisant period were headache (n=5), nausea (n=4), 
insomnia (n=2), malaise (n=2), and sweating (n=2). The majority of the adverse events (95%) 
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occurred during the first 3 days of treatment. None of these adverse events led to treatment 
cessation and 21/22 fully complied with the prescribed treatments.  
The conclusion of the pilot study led to a much larger study 5 years later. This double-
blind RCT by Dauvillers et al. 16 involved 94 narcoleptic patients from 32 centers in five 
European countries. Eligible participants were at least 18 years old with self-reported EDS for 
more than 3 months. Participants were randomly assigned to a treatment group, in which they 
received either a placebo, Modafinil or Pitolisant, an H3 receptor inverse agonist. All 
psychostimulants were stopped 14 days prior to the start of the study. The study started with 
three weeks of flexible dosing based on the investigators discretion. Potential dosing amounts 
included 10mg/20mg/or 40mg a day of Pitolisant or 100mg/200mg/ or 400mg a day of 
Modafinil. This was followed by five weeks of stable dosing. ESS was used to score EDS at 
baseline and at completion of the trial.  In the intention-to-treat analysis, all three treatment 
groups saw a decrease in ESS scores. Patients given the placebo saw the smallest improvement 
in their ESS scores, with reductions of -3.4. While those in the modafinil and pitolisant treatment 
groups saw greater improvements with reductions of –6.9 and -5.8 respectively (Table 4).  
Pitolisant was determined to be superior compared to placebo and noninferior compared 
to modafinil (Table 5). The non-inferiotirty of pitolisant versus modafinil was tested based on a 
non-inferiority margin of 2 ESS points. This value was half the difference between modafinil and 
placebo in previous trials (Mean change of 4.02, 95% CI 0.14-7.09).  
Table 4: ESS scores throughout the trial  
 Baseline Final  Change over Trial  
Placebo Group  
(n=30) 
18.9 (2.5) 15.6 (4.3) -3.4 (4.2)  
Pitolisant Group  
(n=31) 
17.8 (2.5) 12.0 (6.2) -5.8 (6.2)  
Modafinil Group  
(n=33)  
18.5 (2.7)  11.6 (6.0) -6.9 (6.2)  
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Table 5: Treatment Effect (mean difference [95% CI]; p-value) 
Pitolisant vs placebo  Pitolisant vs Modafinil  
-3.0 (-5.6 to -0.4)  
p= 0.024 
0.12 (-2.5 to 2.7)  
p=0.250  
 
Nine severe adverse events occurred during the treatment period; 6 of these was regarded as 
treatment related. One with pitolisant (abdominal discomfort) and five with modafinil 
(abdominal pain, abnormal behavior, amphetamine-like withdrawal symptoms, 
lymphoadenopathy, and inner ear disorder).  
Lastly, the study done by Herring et al.17 was a RCT, double-blind, six sequence cross-
over study consisting of 125 patients with obstructive sleep apnea and refractory EDS. The study 
was conducted at 26 sites across the United States.  Participants were randomized into one of six 
treatment sequences. All sequences included three periods of 2 week treatments of MK-0249 (an 
H3 inverse agonist), Modafinil, and a placebo daily for 2 weeks. Periods 1 and 2 were followed 
by a single-blind wash out period in which participants received a placebo daily for 1 week 
before starting the next period in their respected sequence 
Various doses of MK-0249 were used in the trial. Dosing options of MK-0249 included 
3mg, 5mg, 8mg, 10mg and 12mg. An unblinded statistician determined the appropriate dose for 
each participant. A total of 125 patients were randomized and 103 completed the study.  
At the end of each treatment period, reevaluation of each participants EDS was assessed via the 
ESS scale. All participants who had at least one end-point in at least one treatment period were 
included in the full analysis set.  
Unlike the previously discussed studies, in this study ESS was considered a secondary 
end-point. A conditional approach was prespecified prior to the start of the study. Due to the 
conditional nature of this approach, failure of the primary hypothesis also lead to the failure of 
Peters | H3 Receptor Inverse Agonist & EDS |  
 
9 
 
the secondary hypotheses. Therefore, only descriptive results with a 95% CI for the treatment 
difference were provided and no p-values were given.  
Efficacy was seen most with the top two doses of MK-0249 (10mg + 12mg). These 
dosages were combined into a single group for the analysis. All three groups displayed a 
decrease in average ESS scores. MK-0249 saw the largest improvement with a decrease of 3.99, 
while placebo and modafinil groups saw a smaller improvement with changes of -2.21 and -2.96, 
respectively (Table 6). When compared to placebo, MK-0149 (10mg + 12mg) saw an 
improvement of -1.78 in average ESS scores. This was a much larger improvement than the, -
0.74 ESS difference, seen between modafinil and placebo (Table 7). 
Change from baseline over 2 weeks 
Placebo Group  
(n=116) 
-2.21 (±0.76)  
MK-0249  
(10mg + 12 mg)  
(n=74) 
-3.99 (±1.01)  
Modafinil 
Group  
(n=106) 
-2.96 (±0.79)  
 
 
 
Reasons for discontinuation in the 22 patients were AEs (N=12), withdrawal by patient (N=9) 
and protocol violation (N=1). Patient compliance was evaluated by capsule counts at each visit.  
Discussion: 
The Herring et al.17 study was one of the first studies to be done assessing similar 
therapeutic effects on OSA patients. Treatment with the H3 inverse agonist, MK-0249, showed 
qualitative improvement in ESS scores when compared to baseline scores. However, while these 
results are meaningful and should not be negated, they are not statistically significant. It is 
MK 10+ 12 vs placebo  Modafinil vs placebo  
-1.78 (-2.78 to -0.78)  -0.74 (-1.60 to 0.11) 
Table 7: Treatment Efficacy: ESS differences from placebo 
in least squares mean (95% CI) change from baseline at 
week 2  
 
Table 6: Least squares mean (95% CI) ESS change 
from baseline at week 2 
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evident that more studies need to be done in order to appropriately assess the benefits of H3 
inverse agonists in the OSA population.  
The unique cross sequential design in the Lin J-S et al.15 study allowed the direct 
comparison of the placebo and treatment effects on the same subject. One limitation of this study 
design is the potential “carry over” effects between treatments. In the Lin J-S et al. study, 
patients were asked to discontinue all stimulant medications, and receive one week of placebo 
followed by one week of tiprolisant. It is possible that patients felt more tired than expected 
while withdrawing from their stimulant medication. In addition, subject may have also perceived 
a greater treatment effect from tiprolisant after a not receiving a stimulant for an entire week 
prior. The study done by Herring et al.17 allowed a one week washout period between 
interventions in order to try to eliminate this “carry over” effect.  
The Dauvillers et al.16 and Herring et al.17 studies reported adverse events that resulted in 
participation discontinuation. Throughout this review, there was only one serious adverse event 
related to treatment with an H3 inverse agonist. The patient complained of abdominal pain and 
was in the Dauvillers et al.16 study. The most common side effect noted in all three studies was 
headache and anxiety. The Herring et al. study also had reports of insomnia with treatments 
involving higher doses of the H3 inverse agonist. Further studies should be investigated to 
determine the continuation of these effects with continued treatment.  
It is important to remember that while both narcolepsy and OSA present with clinical 
symptoms of EDS, the etiology of sleepiness is not the same in each condition. While narcolepsy 
occurs due to a deficiency in a neuropeptide in the brain, OSA occurs as a result of a physical 
obstruction of the airway. OSA patients have the physiological ability to regulate sleep-wake 
cycles, while narcoleptic patients do not. The efficacy of H3 inverse agonists may be different 
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between narcolepsy and OSA simply due to the nature of the conditions. Histamine may play a 
more primary role in helping to better regulate the dysfunctional sleep-wake cycle in narcolepsy. 
In contrast, the effects of additional histamine and arousal in OSA patients may just 
symptomatically treat residual EDS. 
Conclusion:  
Life with excessive daytime sleepiness (EDS) can be debilitating, expensive, and 
dangerous. All three studies discussed in this review, show promising results to suggest that 
histamine H3 inverse agonists are effective in treating patients with sleep disorders. The two 
studies involving narcoleptic participants provided the most promising evidence. Similar 
findings in ESS score reduction were also seen in a new study recently published in early 2017 
investigating the effects of pitolisant in reducing daily cataplexy attacks in narcoleptic patients.18 
More studies should be done to prove the significance of H3 inverse agonist use in OSA patients. 
Currently, there is a study finalizing the results of the use of an H3 inverse agonist in 202 OSA 
patients; results are expected to be published in the near future.19 Additional future studies 
should be done to investigate the long-term effects and/or tolerability to use of this new drug 
class. As more is learned about the histaminergic system and the effects of histamine on arousal, 
it is hopeful that more treatment options will become available for all patients suffering from 
EDS.  
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